DDInter1837 DDInter1763
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Toremifene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Toremifene {u} (Compound) upregulates {v} (Gene) LRP10
LRP10 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Toremifene {u} (Compound) downregulates {v} (Gene) MRPS2
MRPS2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Toremifene {u} (Compound) upregulates {v} (Gene) EBP
EBP {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Toremifene {u} (Compound) causes {v} (Side Effect) Pain
Pain {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Toremifene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Toremifene {u} (Compound) upregulates {v} (Gene) LRP10
LRP10 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Toremifene {u} (Compound) upregulates {v} (Gene) CDK19
CDK19 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Toremifene (Compound) upregulates LRP10 (Gene) and LRP10 (Gene) is upregulated by Temsirolimus (Compound)
Toremifene (Compound) downregulates MRPS2 (Gene) and MRPS2 (Gene) is downregulated by Temsirolimus (Compound)
Toremifene (Compound) upregulates EBP (Gene) and EBP (Gene) is downregulated by Temsirolimus (Compound)
Toremifene (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Temsirolimus (Compound)
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Toremifene (Compound) upregulates LRP10 (Gene) and LRP10 (Gene) is downregulated by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Toremifene (Compound) upregulates CDK19 (Gene) and CDK19 (Gene) is upregulated by Sirolimus (Compound) and Sirolimus (Compound) resembles Temsirolimus (Compound)